Halozyme Therapeutics (HALO) Tops Q2 EPS by 4c, Revenues Miss; Maintains FY19 Revenue Guidance Above Consensus

August 6, 2019 6:03 PM

Halozyme Therapeutics (NASDAQ: HALO) reported Q2 EPS of ($0.10), $0.04 better than the analyst estimate of ($0.14). Revenue for the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found